Takip et
Tarik A. Khan
Tarik A. Khan
roche.com üzerinde doğrulanmış e-posta adresine sahip
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade
P Müller, M Kreuzaler, T Khan, DS Thommen, K Martin, K Glatz, S Savic, ...
Science translational medicine 7 (315), 315ra188-315ra188, 2015
3302015
Key interactions of surfactants in therapeutic protein formulations: a review
TA Khan, HC Mahler, RSK Kishore
European journal of pharmaceutics and biopharmaceutics 97, 60-67, 2015
2342015
Concentrated dispersions of equilibrium protein nanoclusters that reversibly dissociate into active monomers
KP Johnston, JA Maynard, TM Truskett, AU Borwankar, MA Miller, ...
ACS nano 6 (2), 1357-1369, 2012
1382012
Advanced methodologies in high-throughput sequencing of immune repertoires
S Friedensohn, TA Khan, ST Reddy
Trends in biotechnology 35 (3), 203-214, 2017
1332017
Accurate and predictive antibody repertoire profiling by molecular amplification fingerprinting
TA Khan, S Friedensohn, AR Gorter de Vries, J Straszewski, ...
Science advances 2 (3), e1501371, 2016
1312016
In Vivo Whole Animal Fluorescence Imaging of a Microparticle-Based Oral Vaccine Containing (CuInSexS2–x)/ZnS Core/Shell Quantum Dots
MG Panthani, TA Khan, DK Reid, DJ Hellebusch, MR Rasch, JA Maynard, ...
Nano letters 13 (9), 4294-4298, 2013
1222013
Deep sequencing in library selection projects: what insight does it bring?
J Glanville, S D’Angelo, TA Khan, ST Reddy, L Naranjo, F Ferrara, ...
Current opinion in structural biology 33, 146-160, 2015
792015
Quantitative assessment of the robustness of next-generation sequencing of antibody variable gene repertoires from immunized mice
V Greiff, U Menzel, U Haessler, SC Cook, S Friedensohn, TA Khan, ...
BMC immunology 15, 1-14, 2014
662014
Comprehensive evaluation and optimization of amplicon library preparation methods for high-throughput antibody sequencing
U Menzel, V Greiff, TA Khan, U Haessler, I Hellmann, S Friedensohn, ...
PloS one 9 (5), e96727, 2014
662014
Advancing therapeutic protein discovery and development through comprehensive computational and biophysical characterization
L Gentiluomo, HL Svilenov, D Augustijn, I El Bialy, ML Greco, A Kulakova, ...
Molecular Pharmaceutics 17 (2), 426-440, 2019
432019
Convergent selection in antibody repertoires is revealed by deep learning
S Friedensohn, D Neumeier, TA Khan, L Csepregi, C Parola, ...
BioRxiv, 2020.02. 25.965673, 2020
402020
Determination of the density of protein particles using a suspended microchannel resonator
E Folzer, TA Khan, R Schmidt, C Finkler, J Huwyler, HC Mahler, ...
Journal of pharmaceutical sciences 104 (12), 4034-4040, 2015
392015
Protein-polydimethylsiloxane particles in liquid vial monoclonal antibody formulations containing poloxamer 188
C Grapentin, C Müller, RSK Kishore, M Adler, I ElBialy, W Friess, ...
Journal of pharmaceutical sciences 109 (8), 2393-2404, 2020
382020
Approaches to mitigate the unwanted immunogenicity of therapeutic proteins during drug development
LI Salazar-Fontana, DD Desai, TA Khan, RC Pillutla, S Prior, ...
The AAPS journal 19, 377-385, 2017
372017
Immunological principles regulating immunomodulation with biomaterials
TA Khan, ST Reddy
Acta biomaterialia 10 (4), 1720-1727, 2014
232014
Biophysical analysis of lipopolysaccharide formulations for an understanding of the low endotoxin recovery (LER) phenomenon
W Correa, K Brandenburg, U Zähringer, K Ravuri, T Khan, ...
International Journal of Molecular Sciences 18 (12), 2737, 2017
222017
Antibody nanoparticle dispersions formed with mixtures of crowding molecules retain activity and in vivo bioavailability
MA Miller, TA Khan, KJ Kaczorowski, BK Wilson, AK Dinin, AU Borwankar, ...
Journal of pharmaceutical sciences 101 (10), 3763-3778, 2012
212012
Adsorption of non-ionic surfactant and monoclonal antibody on siliconized surface studied by neutron reflectometry
Z Zhang, AM Woys, K Hong, C Grapentin, TA Khan, IE Zarraga, ...
Journal of Colloid and Interface Science 584, 429-438, 2021
202021
Subcutaneous HER2 antibody formulations
J Eng-Wong, W Kirschbrown, T Khan, J Lin, S Alavattam, A Garg, ...
US Patent 10,849,849, 2020
92020
High concentration formulation developability approaches and considerations
J Zarzar, T Khan, M Bhagawati, B Weiche, J Sydow-Andersen, ...
MAbs 15 (1), 2211185, 2023
82023
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20